Top Picks Post Q4FY15 Results

Aurobindo Pharma Bajaj Auto Capital First Coal India Mangalam Cement Mastek Pennar Industries Reliance Industries State Bank of India Tech Mahindra



IndiaNivesh Securities Private Limited

e-mail: research@indianivesh.in | Website: www.indianivesh.in



Top Picks Post Q4FY15 Results

Key Highlights:

- INSPL universe aggregate sales decreased by 3.5% YoY v/s our expectation of de-growth of 3.1 %. Oil & Gas along with Capital goods sectors were the biggest laggard which dragged aggregate numbers.
- Excluding oil & Gas & Financials the sales growth for the quarter gone by was 4.1 % YoY v/s our expectation of growth of 2.6%.
- Banking & financials maintained growth on top line at 12.1% v/s growth of 11.6% YoY in Q3FY15.
- For OIL & Gas this was a second consecutive quarter of severe decline in revenues due to fall in crude prices. The sector witnessed decline of 25.6% this quarter v/s 19% YoY decline in Q3FY15.

Performers 20.0 _ 17.8 15.0 12.1 11.0 9.5 7.5 10.0 Laggards 4.9 2.9 5.0 1.3 0.0 FMCG Telecom Cement BFSI E Auto Others Power Pharma -5.0 Cap<mark>ital Goo</mark>d -10.0 -0.1 -15.0 -20.0 -12.4 -25.0 -25.6 -30.0 Source: IndiaNivesh Research

Sales performance of sectors (% YoY)

IndiaNivesh Research




- In terms of EBITDA the companies somehow maintained margins despite sluggish to falling revenue. Against our expectation of growth of ~0.3% in EBITDA on aggregate basis for INSPL Universe, the reported EBITDA actually witnessed growth of 1.7% YoY. Hence there was a beat on our estimates in terms of EBITDA.
- On back of stable NIMs, higher treasury & other income banks/financials witnessed 16.5% YoY growth in pre provisioning profit. Last quarter too BFSI sector witnessed similar rate of growth.
- Falling top line & increased execution expenses resulted in steep decline in EBITDA of Capital goods sector witnessing 33.4% YOY de-growth. IT, Pharma & Others sectors were major negative surprises on EBITDA front.

Particulars	Q4FY15	Q4FY14	Bps yoy change
Power	32.1	27.4	467
BFSI	78.7	75.8	293
Telecom	35.3	32.6	274
Oil & Gas	18.1	16.5	163
FMCG	17.5	16.8	75
Cement	18.7	18.1	62
Auto	12.8	14.0	-113
IT	24.4	26.5	-209
Capital Goods	10.5	13.8	-333
Others	15.0	18.6	- 36 1
Pharma	18.3	25.9	-761
Overall	26.0	24.7	134

EBITDA Margin of Sectors (%)

Sector-wise EBITDA Growth (YoY %)



Source: IndiaNivesh Research

IndiaNivesh Research

Source: IndiaNivesh Research

Top Picks Post Q4FY15 Results




- On adjusted PAT level the disappointment was even more. Against our expectation of decline of 1.7% the actual fall was more severe at 5.5% de-growth YoY. Just want to highlight the fact that previous quarter too there was a decline of ~6% YoY.
- Banks took advantage of favorable yield regime & gained substantially in treasury income. However
 interest income reversals, increased fresh slippages & last quarter to take advantage of lower
 provisioning norms on restructured assets resulted in provisions expenses going up significantly high.
 The heightened provisions expenses resulted in lower adjusted net profit for the sector.

Sector-wise PAT margin (%)

Particulars	Q4FY15	Q4FY14	Bps yoy change
Telecom	7.0	5.3	168
FMCG	13.0	12.2	85
Power	15.0	14.2	76
Oil & Gas	11.0	10.5	54
BFSI	30.2	30.5	-28
Auto	6.5	7.3	-87
Information Techr	19.8	20.8	-96
Capital Goods	5.6	9.1	-349
Others	3.0	7.2	-423
Cement	8.7	13.1	-438
Pharmaceuticals	13.5	18.7	-529
Overall	12.9	13.2	-27

Sector-wise PAT Growth (YoY %)



Source: IndiaNivesh Research

Source: IndiaNivesh Research



Overall Performance

- Pharma, Financials & FMCG were the top 3 performers amongst INSPL universe in terms of revenue growth while Oil/Gas & Capital Goods were worst performers.
- On EBITDA front Power, Telecom & Financials were 3 fastest growing sectors in that order, while the 2 laggards here were Oil/Gas & Capital goods. Telecom was a positive surprise while pharma & others were negative surprises.
- Similarly on adjusted PAT basis Telecom, FMCG & Financials were top 3 while the bottom 3 was Others, Cap Goods & Cement.

Post the Q4FY15 results rating & target price revisions are as follows:

	Rating	Target
Upgrade	9	24
Downgrade	6	26
Neutral	83	48

Source: IndiaNivesh Research



Conclusion:

Overall disappointment from previous quarter continued this quarter too. Usual suspects capital goods & Oil /Gas sectors continued their poor performance. In Q4FY15 results negative surprise came in from poor performance of the 2 most promising & outperforming sectors of the past, namely, IT & Pharma. Growth in top line in pharma has come only due to inorganic expansion (merger of Ranbaxy with Sun & Actavis Europe integration with Auro Pharma).

After 2 consecutive quarters of poor corporate results, market participants have started cutting down on expectation of very high growth in next 2 years. However the estimates for FY16 & FY17 are building in a growth of around 20%. We believe this expectation is too high & needs to be paired down. Our conviction of further downgrades also comes from the fact that 2 months of FY16 are already over. Going by commentary from managements in various post result concalls, we did not find any mention of major uptick or revival in their fortunes. This implies that Q1FY16 will also be bad quarter in terms of corporate performance. It also means asking rate for remaining 3 quarters of FY16 to meet street expectations will go up significantly.

We believe corporate earnings will catch up only if some impetus is provided to macro level growth leading to revival in revenue growth. Perhaps it can come from government spending as private capital is still not coming. Progression of monsoon in India & Global uncertainty from Euro region, confused macro-economic policy indications from USFED are other risk factors for the markets. While we remain invested in markets, we are cautious of stretched valuations despite steep fall of last few days. We stick to stock specific approach. List of stocks, that we like post Q4FY15 results, follows in ensuing pages.

Top Picks: Aurobindo Pharma, Bajaj Auto, Capital First, Coal India, Mangalam Cement, Mastek, Pennar Industries, Reliance Industries, State Bank of India & Tech Mahindra.



Aurobindo Pharma (ARBP)

CMP Rs.1,327 |P/E (FY16E) 19.4x P/E (FY17E) 16.6x | Target Rs.1,600

Investment Rationale

- ARBP has appreciated by 103% and 99% on absolute basis and relative basis, respectively, in past one year. This has been on the back of re-rating as well as earnings upside due to strong execution post resolution of USFDA related issues at some of its manufacturing facilities.
- We continue to remain positive on the stock with implied potential upside of ~20% from current levels. We believe that ARBP is in sweet position to maintain sustained increase in sales as well as profitability over next 2-3 years.
- ARBP has cumulative filing of 376 ANDAs at the end of Q4FY15. The cumulative ANDAs pending for approval stands at 183, which has good mix of complex molecules which would enable not only enhanced sales growth but also improve profitability for sustained period. The upside in earnings is subject to regulatory approval.
- ARBP has ~43 products filed in injectables space and 7 products in controlled substance space. ARBP's R&D effort towards peptides, microspheres as well as hormones would also deliver better growth over 3-5 year period.
- The faster turnaround of acquired Actavis operation in Europe would also help in further improvement in overall margins of the company. At the end of Q4FY15, ARBP has guided for Actavis operation to be PAT positive by the end of FY16.
- There has been pick-up in ARV sales since Q3FY15, resulting in 15% y-y growth for FY15. Management has guided for maintaining momentum based on strong order book for ARV business.

Valuations

At CMP of Rs1,327, the stock is trading at 19.4x FY16E EPS of Rs68.5 and 16.6x FY17E EPS of Rs80. We maintain BUY rating with price target of Rs1,600, based on 20x FY17E earnings

Rs mn	Sales	EBITDA	EBITDA %	ΡΑΤ	EPS	ROE %	P/E	EV/EBITDA	P/BV Di	v Yield %
FY14	80,385	21,328	26.5	14,334	47.2	36.6	28.1	19.7	10.3	0.5
FY15	120,432	25,636	21.3	16,309	56.0	31.6	23.7	16.4	7.5	0.6
FY16E	141,527	31,476	22.2	19,946	68.5	29.2	19.4	13.0	5.6	0.8
FY17E	157,178	36,647	23.3	23,275	80.0	26.3	16.6	10.8	4.4	0.8

Source: Company Filings, IndiaNivesh Research

Bajaj Auto Ltd.



CMP Rs 2199 | Target Rs. 2820 P/E (FY16E) 17.2x | P/E (FY17E) 15.6x

Investment Rationale

- Company has been able to maintain its high margins and return ratios (ROE close to 30%) in relatively tough economic conditions
- Domestic volumes from entry level segment are improving on the back of new launches like Platina and CT100. The company has clocked in sales of 90,000 units in May (up from 45000 units sold in March) and is close to achieving target of 1,00,000 units/month
- We expect strong Q1 numbers based on the strong growth in 3 Wheeler and exports
- Two sources of tailwind for the company:-
 - Softening of Raw material prices Copper, Aluminum and Steel prices have come down which will add to the margins
 - □ Exports picking up in Nigeria, Egypt & Latin America along with depreciating Rupee will make exports more competitive (Company has given a guidance of 11%+ growth in exports in FY16)

Valuations

We expect domestic volumes to improve on the back of new launches like Pulsar RS200,new CT100 and Platina. Further exports growth is also back on track. We expect revenue to grow at a CAGR of 10.4% from FY15 - FY17E on the back of 9.4% CAGR growth in volume. EBITDA margins expected to be in the range of 20% and EPS is expected to grow at a CAGR of 20% from FY15 - FY17E. At CMP of Rs 2199 the stock is trading at PE multiple of 15.6x FY17E EPS. We maintain BUY rating on the stock with target price of Rs. 2820 (20x FY17E EPS).

Rs mn	Net sales	EBITDA	Adj. PAT E	PS(Rs.)	EBITDA Margin (%)	ROE (%)	P/E(x)	EV/EBITDA(x)
FY15	216120	41165	28137	97	19.0	28	22.7	16.05
FY16E	233897	47818	36950	128	20.4	32	17.2	13.72
FY17E	263651	53315	40804	141	20.2	30	15.6	12.23

Source: Company Filings; IndiaNivesh Research Note: CMP as of 05/06/2015

IndiaNivesh Research

Top Picks Post Q4FY15 Results



Capital First Limited (CFL)

CMP Rs 381/- |P/ABV (FY16E) 2.1x|P/ABV (FY17E) 1.9x Target Rs 465/-

Investment Rationale

- Growth story to continue strongly: Asset under Management (AuM) of CFL has grown at a CAGR of 44% over FY11-15 which is one of the best in the industry. As a strategy to focus on retail segment (which includes Consumer Durable Loans, Two wheeler Loans, Loan against Property, Mortgage Loans and Small Business Loans), AUM of CFL has gradually moved towards retail loan book from 10% in FY10 to 84% in FY15. As a result wholesale loan book (which includes loans given to real estate developers) has come down to 16% from 90% over the same period. We believe CFL is well poised to grow at 28% CAGR in FY15-17E mainly led by retail credit assets.
- Change in borrowing mix to improve NIMs: Net Interest Margin (Calc) of CFL has increased to 5.8% in FY15 from 4.5% in FY13. We expect the company will be able to improve its margins further from current level of 5.8% in FY15 to 6.0% in FY16 with change in borrowing mix and company's increasing presence in high yielding segments (i.e. two wheeler and consumer durable loans).
- Well maintained asset quality: CFL was successful in maintaining its asset quality with one of the lowest levels of Gross and Net NPAs in the industry at 0.69% and 0.17% respectively as of Q4FY15. This is based on the fact that asset mix has shifted towards comparatively safer segments like LAP, Mortgage, two wheelers and Consumer Durables v/s riskier segments of developer loans. We don't expect any significant deterioration in asset quality and expect Gross NPA / Net NPA to remain at 0.8% / 0.3% by FY17E.
- Strong capital adequacy ratio: Capital adequacy of CFL remains strong and ahead of regulatory requirement at 23.5% with tier I capital of 18.8%. Recent capital infusion of Rs 3.0 bn through QIP has boosted the company's Capital adequacy ratio making it one of the best amongst peers. Overall liquidity position is comfortable and quite high to sustain medium term growth. Hence, the risk of dilution is minimal in coming period.
- Return ratios to improve further: Return ratios of CFL was lower because of the fact that company changed its accounting policy of amortizing processing fees over the tenure of the loan as against earlier policy of booking the said fees upfront from FY13. However, normalization of previous year amortizations from FY15 onwards along with improving efficiency in terms of lower cost to income (expense) ratio is likely to help strong bottom line CAGR growth of 34% over FY15-17E. With consistency in credit growth, improvement in margins and optimization of cost, we expect RoE / RoA (calc) to improve to 12% / 1.4% by FY17E from 8% / 1.1% in FY15.



Valuations

The company has shown overall stellar performance during FY15. The robust profit growth in FY15 was due to number of steps taken by the company which were (1) Robust 28% y-o-y growth in retail loan portfolio in FY15, (2) NIM (calc) improved to 5.8% in FY15 from 4.7% in FY14 and (3) Cost control initiatives which helped to reduce cost income ratio significantly to 58.7% in FY15 from 70.3% in FY14. Due to the company's prudent management practices, focused lending approach, quicker turnaround time and healthy adequacy position, we believe the current growth momentum can continue over FY15-17E. At CMP of Rs 381/-, CFL is trading at P/ABV of 2.1x and 1.9x for FY16E and FY17E respectively. We continue to maintain 'BUY' rating with long term positive view on the stock and price target of Rs 465/- (2.3x P/ABV for FY17E).

Financials

Rs mn	NII	РАТ	EPS (Rs)	ROA (%)	ROE (%)	BV (Rs)	ABV (Rs)	P/E	P/BV	P/ABV
FY12	3,063	922	14	2.0	11.9	126	126	9.9	1.1	1.1
FY13	3,084	698	10	1.1	8.0	134	134	16.5	1.2	1.2
FY14	4,038	370	5	0.4	3.6	138	138	34.1	1.1	1.1
FY15	6,277	1,120	12	1.1	8.4	169	167	31.0	2.3	2.3
FY16E	8,232	1,681	18	1.4	10.4	185	181	20.6	2.1	2.1
FY17E	9,749	2,003	22	1.4	11.5	204	198	17.3	1.9	1.9

Source: Company, IndiaNivesh Research; Standalone, CMP as on 05/06/2015

IndiaNivesh Trust.....we earn it.

Coal India Ltd. (CIL)

Investment Rationale

CMP Rs 406 | Target Rs. 467 P/E (FY16E) 14.9x | P/E (FY17E) 13.4x

- After a couple of years of stagnant production levels in the past, CIL finally delivered strong performance in FY15. Production grew by ~6.9% in FY15 on the back of a concerted push by the government. The government has set a gross output target of one billion tonnes of coal by 2019-20, which is around double the current production. In near term the company has guided 12% off take volume growth to 550 MT and 11% production volume growth to 550 MT in FY16. However, we forecast FY16 production at 529 MT (+7% YoY); off-take 523 MT (+7%).
- Coal Ministry has allowed CIL to revert to the old system, removing the cap on e-auction volumes with effect from April 2015. This means Coal India will now be able to increase its e-auction volumes to 10% of total sales (vs 7% of earlier cap) and may go up to 12% as used to be in good times. This will boost CIL's profitability as auctioned coal fetches 35-45% more than notified price.
- The company has a strong balance sheet, with cash & cash equivalent at Rs ~592bn (Rs. 94/share) at end of FY15. In previous 2 years the company has given dividend @100%. We believe the dividend payout will remain healthy, and would be ~50% in coming years.
- CIL is one of the lowest cost coal producers globally (\$22/t compared with the global thermal coal average of \$35/t). 90% of CIL's mines are open cast, which have stable ground conditions, relatively simple geological structures and a low stripping ratio.

Valuations

We believe that company is likely to show strong performance in medium to long term (expect CAGR production growth of 7% in next five years) due to strong domestic coal demand and monopoly in coal production in India. At CMP of Rs 406, stock is trading at 13.4X of its FY17E EPS We maintain buy rating on the stock with DCF based target price of Rs 467.

Y E March	Net sales(Rs. mn)	EBITDA(Rs. mn)	j. PAT(Rs. mn)	EPS(Rs.)	EBITDA margin(%)	PE(x)	MC/sales(x)
FY15	741,201	173,354	137,266	21.7	21.1	18.7	3.5
FY16E	800,644	189,493	171,842	27.2	23.7	14.9	3.2
FY17E	899,775	217,302	191,787	30	24.2	13.4	2.9

Source: Company Filings; IndiaNivesh Research Note: CMP as of 7/06/2015

IndiaNivesh Research

Top Picks Post Q4FY15 Results

Mangalam Cement



CMP Rs.230 | EV/EBITDA (FY16E) 8.2x EV/EBITDA (FY17E) 7.0x | Target Rs.376

Investment Rationale

Strong FY15 Operating Performance:

- On back of capacity addition of 1.25 mnt (total capacity-3.25 mnt), Mangalam cement has reported robust performance for FY15.
- Sales of the company has increased by 32.1% to Rs 9,084mn and EBITDA margin also expanded by 179 bps to 8.5%; led by various cost savings measures taken by the company.
- EBITDA per th of the company also improved by 34% to Rs 343

Large Operating Leverage and Infra sector potential:

- Mangalam Cement has potential to improve its sales and margin from current levels without incurring further capex as current capacity utilization of the company stands at ~70%
- As New government has announced many ambitious plans like more road length construction every day, housing for all and smart cities etc; even a small pick-up in infra activity can boost the plant utilization levels of company. This will further improve EBITDA/tn ratio of the company from current levels.

Stable debt level to improve net Profit:

- Despite robust operating performance, company adj net profit declined by ~28% in FY15 due to high interest cost.
- However post the completion of capex plan in FY14, debt of the company has stabilized at Rs 3,447 mn in Q4FY15(down 3% y-o-y). This will improve the net profit of the company in FY16E and FY17E, led by strong operating performance and stable interest cost.

Valuation

At CMP of Rs 230, Mangalam Cement is trading at FY16E and FY17E, EV/EBITDA multiple of, 8.2x and 7.0x, respectively. We maintain BUY rating on the stock with PT of Rs 376.

Rs Mn	Net Sales	EBITDA	Net Profit	Equity Capital	EPS (Rs)	EV/EBITDA
FY14	6,875	460	296	267	11.1	13.7
FY15	9,084	770	214	267	8.0	12.4
FY16E	10,990	1,173	501	267	18.8	8.2
FY17E	12,263	1,376	601	267	22.5	7.0
	1 1: 11: 1					

Source: Company, IndiaNivesh Research



Mastek Ltd. (Mastek)

CMP : Rs.460 | P/E (FY16E) 31.9x P/E (FY17E) 12.5x Target Price: Rs.724

- Underpenetrated Industry: According to Garner Property & Casualty (P&C) insurance industry spends yearly ~\$15 bn on ageing legacy systems & services. Out of this \$6-7 bn could migrate to 3rd party Software & Services vendors like Majesco-US. Currently less than 10% of this opportunity has been penetrated, Majesco is well placed to gain from this Industry transition. Additionally, the recent M&A (COVR and Agile) is likely to bring huge cross-sell and up-scale opportunity.
- Re-rating Potential: Demerger [Services & Platform] and listing of Majesco-US on NYSE could lead to significant re-rating and improvement in performance going-ahead. The standalone Services business profitability and ROE is likely to improve, which would lead to P/E multiple expansion. On the other side listing on NYSE will bring re-rating to platform business. Currently platform business is valued at 0.6x (v/s 6.7x P&C platform of peer) of EV/Sales.
- Elixir North America success remains an additional trigger: Management expect Elixir North America (L&A platform) beta version to be implemented by the end of CY15. Once the implementation is through and tested, Foresters could be used as a referral model while pitching to other life & pension insurers in North America.

Valuation: At CMP of Rs.460, the stock is trading at P/E multiple of 32.1x FY16E and 12.7x FY17E earning estimate. We value Software & Services business at P/E multiple of 8.5x FY17E (TP Rs.175) and Insurance vertical at EV/Sales multiple of 1.7x FY17E (TP Rs.549). We have BUY rating with SoTP based TP of Rs.724.

YE March					EBITDA			
(Rs. Mn)	Net Sales	PBDIT	Adj PAT	EPS (Rs)	Margin (%)	ROE (%)	PE (x)	EV/EBITDA (x)
FY15A	10,019	557	178	7.9	5.6	3.1	50.8x	17.3x
FY16e	13,259	1,079	256	12.5	8.1	4.6	31.9x	8.9x
FY17e	16,602	1,662	745	32.1	10.0	11.1	12.5x	5.8x

Source: Company Filings; IndiaNivesh Research

Pennar Industries



CMP Rs.45 | P/E (FY16E) 9.9x P/E (FY17E) 7.1x | Target Rs.70

Investment Rationale

Strong FY15 Performance:

- For the full year FY15, Pennar industries reported robust performance both on top-line and margin front.
- Top-line of the company increased by 12.7% to Rs 12,675 mn led by strong growth in systems/projects and PEBS segment. Margin expansion across all business segments led to EBITDA margin improvement from 8% (FY14) to 9.3% (FY15). Net profit of the company increased by 38.4% to Rs 359 mn in FY15.

Large order Book to help in growth in FYY16E and FY17E:

- Out of six business segments of the company, three are order book based. Current Total order book of the company stands at Rs 5,260 mn.
- Systems and Projects segment has order book of Rs 1,560 mn (solar-Rs 600 mn and railways-960 mn) and PEBS segment has order book of Rs 3,700 mn (as per DRHP filing). This large order book will help Pennar to continue high growth in FY16E and FY17E as well.

Listing of High growth business of PEBS:

PEBS (66.85% subsidiary of Pennar) is one of the leading custom designed building systems solutions provider in the country. PEBS revenue has increased at a CAGR of 35.6% over FY11-14 period. We expect separate listing of PEBS (DRHP filed with SEBI) will help company to unlock the value of this high growth business.

Valuation

• At CMP of Rs 45, Pennar Industries is trading at FY16E and FY17E, PE multiple of, 9.9x and 7.1x, we maintain BUY rating on the stock with revised target price of Rs.70 (11x FY17E EPS).

Net Sales	EBITDA	Adj. PAT	Equity Capital	EPS (Rs)	PE (x)
10,745	898	259	658	2.0	22.8x
12,675	1,175	359	658	2.7	16.5x
15,480	1,461	599	658	4.6	9.9x
19,376	1,839	839	658	6.4	7.1x
	10,745 12,675 15,480	10,74589812,6751,17515,4801,461	10,74589825912,6751,17535915,4801,461599	10,74589825965812,6751,17535965815,4801,461599658	10,7458982596582.012,6751,1753596582.715,4801,4615996584.6

Consolidated Financials Source: Company, IndiaNivesh Research



Reliance Industries Ltd. (RIL)

Investment Rationale

CMP Rs. 887 | Target Rs.1,111 (14x FY16E P/E) P/E (FY16E) 11.4x | P/E (FY17E) 9.4x

- Singapore GRMs which fell to ~USD4.8 /bbl levels during Q2FY15 have recovered back in past few months boosted by gasoline (US refinery strikes) and naphtha cracks. In Q4FY15 RIL's GRM stood at USD10.1/bbl (v/s USD9.3/bbl in Q4FY14 and USD7.3/bbl in Q3FY15. We believe the recent margin uptick and rupee deprecation will help to support refining EBIT margin of RIL going forward.
- Further USD 4 bn Petcoke Gasification project is under rapid execution which expected to provide competitive energy costs. RIL's dependency on imported gas will decrease with completion of coke gasification and gross refining margin (GRM) will improve by \$2-2.5 per barrel.
- Besides the coke gasification project, RIL has earmarked USD 4 billion for a petrochemicals project in Jamnagar that will include a cracker unit. This project is expected to be commissioned in H2FY16 and would nearly double the ethylene capacity to 3.3 million tonnes a year. Further ongoing Polyester expansion and new off-gases cracker will add further value in petchem profitability.
- RIL reported ROE of 11.3% in FY15, down 50 bps YoY. The key reason for decline in ROE was increase of Rs 750bn in CWIP under the ongoing capex programme that pulled down asset turnover sharply. We expect ROE to improve from FY17, when its large projects commence and gas volumes increase.

Valuation

Though RIL's FY16e earnings growth is likely to be muted owing to start-up losses in the telecom business and weak shale gas economics owing to the sharp fall in US gas price, we expect the next earnings growth to come in RIL in FY17, when its large core projects get commissioned. At CMP Rs. 887 stock is trading at 11.4x FY16E EPS which is lower than its mean of 15x. We maintain BUY rating on the stock with target price of Rs. 1111 (based on 14x FY16e earnings).

Y E March	Net sales(Rs. mn)	EBITDA(Rs. mn)	Adj. PAT(Rs. mn)	EPS(Rs.)	EBITDA margin(%)	PE(x)	EV/EBITDA
FY15	3,754,350	384,920	235,660	80	10.3	11.3	10.3
FY16E	3,287,000	4,305,420	250,734	79	131.0	11.4	9.2
FY17E	3,773,000	5,404,740	305,254	97	143.2	9.4	7.3

Source: Company Filings; BL, IndiaNivesh Research Note: CMP as of 7/06/2015



State Bank of India (SBI)

CMP Rs 255 |P/ABV (FY16E) 1.7x |P/ABV (FY17E) 1.6x Target Rs 370

Investment Rationale

- Biggest beneficiary of revival in economy: SBI, being a largest bank in Indian banking sector, remains the biggest beneficiary of revival in economy by way of pick up in loan growth and improvement in asset quality. We believe bank can easily grow its loan book at 10.5% CAGR over FY15-17E with upward bias if corporate capex picks up significantly. With market leadership positioning in Home and Auto loan segment, growth in retail for SBI continues to remain higher.
- NIMs to remain healthy: NIMs (Calc) of SBI has been in the range of 3.2-3.4% in last 3 years which is one of the best amongst public sector banking space. Despite recent decline in base rate, we believe SBI is well positioned to maintain its margins at current levels of 3.2% both for FY16E and FY17E.
- Asset quality to stabilize in H2FY16E: Asset quality for SBI was impacted in FY14 which is inline with industry trend. However in FY15, bank was successful in improving its Gross and Net NPA by 70 and 45 bps yoy to 4.3% and 2.1% partly led by sale of assets to ARC. Fresh slippages were lower at Rs 294 bn in FY15 compared to Rs 415 bn in FY14. However fresh restructuring continues to remain higher at Rs 230 bn in FY15 (Rs 118.9 bn in Q4FY15) as compared to Rs 253 bn in FY14 (Rs 76.4 bn in Q4FY14). We expect asset quality for SBI to improve in H2FY16 led by improvement in macros.
- Capital adequacy remains higher: Capital adequacy of SBI remains healthy at 12% with tier I capital of 9.6% which is ahead of regulatory requirement. SBI is likely to raise capital of Rs 150 bn which will help in growing its loan book and improve capital adequacy further.

Valuations

SBI remains our top pick in public sector banking space as it remains the biggest beneficiary of revival in economy. Although asset quality improvement in FY15 has largely come from asset sale to ARC, even after adjusting for the same, asset quality would have been stable; which is key positive. We recommend buy on SBI with SOTP based target price of Rs 370.

(Rs mn)	NII	ΡΑΤ	EPS (Rs)	ROA (%)	ROE (%)	BV (Rs)	ABV (Rs)	P/E (x)	P/BV (x)	P/ABV (x)
FY14	492,822	108,912	15	0.6	10.0	158	117	17.5	1.6	2.2
FY15	550,153	131,016	18	0.7	10.6	172	135	14.5	1.5	1.9
FY16E	607,730	156,762	21	0.7	11.6	186	148	12.3	1.4	1.7
FY17E	665,545	184,103	24	0.8	12.4	206	163	10.5	1.2	1.6

Source: IndiaNivesh Research



Tech Mahindra Ltd. (TechM)

CMP : Rs.551 | P/E (FY16E) 17.1x P/E (FY17E) 13.6x Target Price: Rs.749

- Strong Revenue Visibility: TechM management sounded confident on future revenue outlook on back of four prong strategy. Management intent to continue its investment on following: (I) high SG&A spending in momentum verticals [Telecom, BFSI, Manuf. & Eng.], (II) launch of new platforms in BPO space, (III) higher investment in product & innovation, and (IV) focus on M&A in new age IT & newer geographies. On back of strong growth momentum and large deal wins, we maintain FY16E/FY17E \$-revenue growth to 20.2%/20.1% Y/Y with INR/USD realization rate 62.6 in each year.
- Health Deal Pipeline: Given the large deal pipeline, TechM expect strong traction in key verticals like BFSI, healthcare, manufacturing and retail. The company's two-pronged strategy to expand enterprise business also looks promising (end-to-end offerings in leadership vertical like manufacturing and niche offerings-led in entry level verticals like BFSI). In Q4FY15, TechM won deals worth of US\$165mn and indicated that while deal closures was slow but deal pipeline looks promising.
- Strong Margin Outlook: The current quarter dip in the EBITDA margin was largely due to the salary-hike and LCC integration. We expect pick-up in EBITDA margin from the current level on back of various operating levers and stable currency outlook to 19.8% in FY16E (v/s 18.4% in FY15E).

Valuation: At CMP of Rs.551, the stock is trading at 17.1x FY16E and 13.6x FY17E EPS estimate. Strong multi-year and multi-million dollar deal wins along with inorganic expansion increase medium-term revenue visibility. We expect smooth ramp-up of these recent large deal wins and also see quick integration benefits (cross-selling) of recent acquisitions. We have BUY rating with target price of Rs.749 on the stock.

YE March				EBITDA			EV/EBITDA		
(Rs. Mn)	Net Sales	PBDIT	Adj PAT	EPS (Rs)	Margin (%)	ROE (%)	PE (x)	(x)	
FY15A	2,26,213	41,529	26,277	26.7	18.4	27.6	20.6x	16.7x	
FY16e	2,73,032	54,051	31,729	32.3	19.8	31.5	17.1x	13.5x	
FY17e	3,27,955	64,378	39,822	40.5	19.6	32.9	13.6x	11.1x	

Source: Company Filings; IndiaNivesh Research



RESEARCH TEAM

Daljeet S. Kohli Head of Research

Tel: +91 22 66188826 daljeet.kohli@indianivesh.in Amar Mourya Research Analyst Tel: +91 22 66188836 amar.mourya@indianivesh.in

Abhishek Jain Research Analyst Tel: +91 22 66188832 abhishek.jain@indianivesh.in

Prerna Jhunjhunwala Research Analyst Tel: +91 22 66188848 prerna.jhunjhunwala@indianivesh.in

Yogesh Hotwani Research Analyst Tel: +91 22 66188839 yogesh.hotwani@indianivesh.in

Tushar Manudhane Research Analyst Tel: +91 22 66188835 tushar.manudhane@indianivesh.in

Jaisheel Garg Research Analyst Tel: +91 22 66188840 jaisheel.garg@indianivesh.in Aman Vij Research Analyst Tel: +91 22 66188818 aman.vij@indianivesh.in

Kaushal Patel Research Associate Tel: +91 22 66188834 kaushal.patel@indianivesh.in

Rahul Koli Research Associate Tel: +91 22 66188833 rahul.koli@indianivesh.in

Abhitesh Agarwal Research Associate Tel: +91 22 66188823 abhitesh.agarwal@indianivesh.in

Harshraj Aggarwal Research Associate Tel: +91 22 66188879 harshraj.aggarwal@indianivesh.in



DISCLAIMER

This document has been prepared by IndiaNivesh Securities Private Limited ("INSPL"), for use by the recipient as information only and is not for circulation or public distribution. INSPL includes subsidiaries, group and associate companies, promoters, employees and affiliates. INSPL researches, aggregates and faithfully reproduces information available in public domain and other sources, considered to be reliable and makes them available for the recipient, though its accuracy or completeness has not been verified by INSPL independently and cannot be guaranteed. The third party research material included in this document does not represent the views of INSPL and/or its officers, employees and the recipient must exercise independent judgement with regard to such content. This document has been published in accordance with the provisions of Regulation 18 of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. This document is not to be altered, transmitted, reproduced, copied, redistributed, uploaded or published or made available to others, in any form, in whole or in part, for any purpose without prior written permission from INSPL. This document is solely for information purpose and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. Recipients of this document should be aware that past performance is not necessarily a guide for future performance and price and value of investments can go up or down. The suitability or otherwise of any investments will depend upon the recipients particular circumstances. INSPL does not take responsibility thereof. The research analysts of INSPL have adhered to the code of conduct under Regulation 24 (2) of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. This document is based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Nothing in this document constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or appropriate to recipients' specific circumstances. INSPL does not accept any responsibility or whatever nature for the information, assurances, statements and opinion given, made available or expressed herein or for any omission or for any liability arising from the use of this document. Opinions expressed are our current opinions as of the date appearing on this document only. The opinions are subject to change without any notice. INSPL directors/employees and its clients may have holdings in the stocks mentioned in the document.

This report is based / focused on fundamentals of the Company and forward-looking statements as such, may not match with a report on a company's technical analysis report

Each of the analysts named below hereby certifies that, with respect to each subject company and its securities for which the analyst is responsible in this report, (1) all of the views expressed in this report accurately reflect his or her personal views about the subject companies and securities, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report: Daljeet S Kohli, Amar Maurya, Abhishek Jain, Yogesh Hotwani, Prerna Jhunjhunwala, Kaushal Patel, Rahul Koli, Tushar Manudhane & Dharmesh Kant.



DISCLAIMER (contd...)

Following table contains the disclosure of interest in order to adhere to utmost transparency in the matter:

	Disclosure of Interest Statement					
1	Details of business activity of IndiaNivesh Securities Private Limited (INSPL)	INSPL is a Stock Broker registered with BSE, NSE and MCX - SX in all the major segments viz. Cash, F & O and CDS segments. INSPL is also a Depository Participant and registered with both Depository viz. CDSL and NSDL. Further, INSPL is a Registered Portfolio Manager and is registered with SEBI.				
2	Details of Disciplinary History of INSPL	No disciplinary action is / was running / initiated against INSPL				
3	Details of Associates of INSPL	Please refer to the important 'Stock Holding Disclosure' report on the IndiaNivesh website (investment Research Section - <u>http://www.indianivesh.in/Research/Holding_Disclosure.aspx?id=10</u> link). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. INSPL and its affiliates may have investment positions in the stocks recommended in this report.				
4	Research analyst or INSPL or its relatives'/associates' financial interest in the subject company and nature of such financial interest	No (except to the extent of shares held by Research analyst or INSPL or its relatives'/associates')				
5	Research analyst or INSPL or its relatives'/associates' actual/beneficial ownership of 1% or more in securities of the subject company, at the end of the month immediately preceding the date of publication of the document.	Please refer to the important 'Stock Holding Disclosure' report on the IndiaNivesh website (investment Research Section - <u>http://www.indianivesh.in/Research/Holding_Disclosure.aspx?id=10</u> link). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. INSPL and its affiliates may have investment positions in the stocks recommended in this report.				
6	Research analyst or INSPL or its relatives'/associates' any other material conflict of interest at the time of publication of the document	No				
7	Has research analyst or INSPL or its associates received any compensation from the subject company in the past 12 months	No				
8	Has research analyst or INSPL or its associates managed or co-managed public offering of securities for the subject company in the past 12 months	Νο				
9	Has research analyst or INSPL or its associates received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months	No				
10	Has research analyst or INSPL or its associates received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months	No				
11	Has research analyst or INSPL or its associates received any compensation or other benefits from the subject company or third party in connection with the document.	Νο				
12	Has research analyst served as an officer, director or employee of the subject company	No				
13	Has research analyst or INSPL engaged in market making activity for the subject company	No				
14	Other disclosures	No				

DISCLAIMER (contd...)



INSPL, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. This information is subject to change, as per applicable law, without any prior notice. INSPL reserves the right to make modifications and alternations to this statement, as may be required, from time to time.

Definitions of ratings

BUY. We expect this stock to deliver more than 15% returns over the next 12 months.

HOLD. We expect this stock to deliver -15% to +15% returns over the next 12 months.

SELL. We expect this stock to deliver <-15% returns over the next 12 months.

Our target prices are on a 12-month horizon basis.

Other definitions

NR = Not Rated. The investment rating and target price, if any, have been arrived at due to certain circumstances not in control of INSPL

CS = Coverage Suspended. INSPL has suspended coverage of this company.

UR= Under Review. Such e invest review happens when any developments have already occurred or likely to occur in target company & INSPL analyst is waiting for some more information to draw conclusion on rating/target.

NA = Not Available or Not Applicable. The information is not available for display or is not applicable.

NM = Not Meaningful. The information is not meaningful and is therefore excluded.

Research Analyst has not served as an officer, director or employee of Subject Company

One year Price history of the daily closing price of the securities covered in this note is available at <u>www.nseindia.com</u> and <u>www.economictimes.indiatimes.com/markets/stocks/stock-quotes.</u> (Choose name of company in the list browse companies and select 1 year in icon YTD in the price chart)





IndiaNivesh Securities Private Limited

601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800 / Fax: (022) 66188899

e-mail: research@indianivesh.in | Website: www.indianivesh.in

IndiaNivesh Research

Top Picks Post Q4FY15 Results